Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone

Not yet recruiting 80 enrolled Cairo University

RandomizedParallel-groupDouble-blindPrevention

Summary

While Carbetocin is effective in reducing PPH, the combination of oxytocin, Tranexamic acid, and Ergot derivatives may offer additional benefits in high-risk populations. We hypothesize that the combination regimen will reduce PPH incidence and severity compared to Carbetocin alone and may be more cost effective

Timeline

Start: 2026-01-01
Primary completion: 2026-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Carbetocin	Peptide	100 ug	Intravenous
Subject	Methylergonovine	Small molecule	0.2 mg/ml	Intramuscular
Subject	Oxytocin	Peptide	5 iu	Intravenous
Subject	Oxytocin	Peptide	10 iu	Intravenous
Subject	Tranexamic Acid	Small molecule	1 g	Intravenous

Indications

No indication recorded.